Poxel Announces Election of Pierre Legault as Chairman of the Board of Directors

POXEL SA (Euronext - POXEL - FR0012432516), a clinical-stage biopharmaceutical company focused on the development of novel treatments for type 2 diabetes and metabolic disease, today announced that Pierre Legault has been appointed the new Chairman of the Board of Directors. Mr. Legault joined Poxel's Board of Directors in February 2016 and will succeed Dr. Thierry Hercend, who will continue to support Poxel as a member of its Board.

Mr. Legault has over 35 years of experience working in the pharmaceutical and biotechnology industry. He is a member of the Board of Tobira Therapeutics (Chairman of audit committee), Iroko Pharmaceuticals and NephroGenex. Over the cause of his career, Mr. Legault served as chief executive officer, president and chief financial officer of several public companies including Eckerd Pharmacies, NephroGenex, OSI Pharmaceuticals and Rite Aid and held several senior positions with Sanofi-Aventis and predecessor companies. Mr. Legault studied International Finance, Business & Commerce and earned an MBA in Marketing from McGill University in Montreal, Canada. Additionally, he completed the Executive Masters Program for InfoTechnology & Services at Harvard Business School and he is a CPA.

Read full article: FirstWord Pharma, April 18, 2016